Get all your news in one place.
100's of premium titles.
One app.
Start reading
MarketBeat
MarketBeat
MarketBeat

Bicara Therapeutics Touts Cancer Drug Progress Ahead of 2026 Pivotal Data

Bicara Therapeutics (NASDAQ:BCAX) said its lead cancer drug candidate, ficerafusp alfa, remains on track for pivotal data in head and neck cancer in mid-2026, as the company outlined its development strategy and competitive positioning at the Bank of America Healthcare Conference.

Ryan Kohlhepp of Bicara told Bank of America analyst Tazeen Ahmad that the Boston-based biotechnology company is focused on large-molecule bifunctional antibodies for solid tumor oncology. Its lead program, ficerafusp alfa, targets EGFR and TGF-beta, with the goal of using EGFR-mediated tumor targeting to deliver TGF-beta inhibition more effectively to tumors.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.